A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Avidoxy
(United States) [Available] ,Doryx
(United States) [Available] ,Doryx MPC
(United States) [Available] ,Oracea
(United States) [Available] ,TargaDOX
(United States) [Available]Synonyms :
doxycycline
Class :
Antibiotics & Tetracycline derivatives
Brand Name :
Avidoxy
(United States) [Available] ,Doryx
(United States) [Available] ,Doryx MPC
(United States) [Available] ,Oracea
(United States) [Available] ,TargaDOX
(United States) [Available]Synonyms :
doxycycline
Class :
Antibiotics & Tetracycline derivatives
Dosage forms & StrengthsÂ
CapsuleÂ
50 mgÂ
100 mgÂ
100 mgÂ
50 mgÂ
100 mgÂ
Capsule delayed-releaseÂ
40 mgÂ
Solution reconstitutedÂ
100 mgÂ
SuspensionÂ
25 mg/5 ml (60ml)Â
SyrupÂ
50 mg/5 ml (473 ml)Â
TabletÂ
20 mgÂ
50 mgÂ
75 mgÂ
100 mgÂ
150 mgÂ
Tablet delayed-releaseÂ
50 mgÂ
80 mgÂ
200 mgÂ
120 mgÂ
75 mgÂ
100 mgÂ
150 mgÂ
Duration of <1 year:
100
mg
Orally 
twice a day
2
weeks
Duration of ≥1 year: 100 mg Orally twice a day 4 weeks
200
mg
each day orally or intravenously divided twice daily
Intravenous dose can be once daily
Maintenance Dose
100-200 mg each day orally or intravenously divided twice daily
Intravenous dose can be once daily
200
mg
Orally 
as a single dose
100 mg orally/IV 2 times a day 7–14 days
Upper Respiratory Tract ConditionsÂ
Initial dose of 200 mg intravenously on day 1 and given in 1 infusion or 2 infusions
Maximum dose: 100 mg to 200 mg per day intravenously
Initial dose of 200 mg orally on day 1 and given in 2 doses – 100 mg for every 12 hours
Maximum dose: 100 mg once a day orally or 50 mg for every 12 hours orally
Dosage forms & StrengthsÂ
Capsule, Oral:Â
50 mgÂ
100 mgÂ
100 mgÂ
50 mgÂ
100 mgÂ
Capsule delayed-release:Â
40 mgÂ
Solution reconstituted, IV:Â
100 mgÂ
Suspension, Oral:Â
25 mg/5 ml (60ml)Â
Syrup, Oral:Â
50 mg/5 ml (473 ml)Â
TabletÂ
20 mgÂ
50 mgÂ
75 mgÂ
100 mgÂ
150 mgÂ
Tablet delayed releaseÂ
50 mgÂ
80 mgÂ
200 mgÂ
120 mgÂ
75 mgÂ
100 mgÂ
150 mgÂ
Children >8 years and adolescents: 50 to 100 mg orally once or twice a day (depends on the severity of infection and symptoms)
Infants, children, and adolescents:
4.4 mg/kg oral as a single dose (do not exceed 200mg/dose)
Children >8 years and adolescents:
1 to 2 mg/kg per dose twice a day for 10 days
Refer to adult dosingÂ
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
may diminish the absorption when combined with iron preparations
may diminish the absorption when combined with iron preparations
may diminish the absorption when combined with iron preparations
may diminish the absorption when combined with iron preparations
doxycycline: it may increase the risk of methemoglobinemia associated agents
doxycycline: it may increase the risk of methemoglobinemia associated agents
doxycycline: it may increase the risk of methemoglobinemia associated agents
doxycycline: it may increase the risk of methemoglobinemia associated agents
doxycycline: it may increase the risk of methemoglobinemia associated agents
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
magnesium salts may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
antacids may decrease the absorption of tetracyclines
may diminish the absorption of iron preparations
may diminish the serum concentration when combined with tetracyclines
may diminish the serum concentration when combined with tetracyclines
may diminish the absorption of magnesium salts
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
may have a decreased absorption when combined with tetracyclines
aluminum hydroxide/magnesium carbonateÂ
may decrease the serum concentration of antacids
aluminum hydroxide/magnesium carbonateÂ
may decrease the serum concentration of antacids
may have a decreased therapeutic efficacy when combined with doxycycline
may increase the therapeutic efficacy of each other when combined
oral form of aluminum hydroxide inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
may enhance the toxic effects of doxycycline
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
interaction of both drugs may lead to respiratory depression
doxycycline may reduce the therapeutic effects of BCG vaccine
oral form of bismuth subsalicylate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium acetate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium carbonate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium chloride inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
oral form of calcium citrate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
calcium gluconate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
calcium iron inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
doxycycline may reduce the therapeutic effects of cholera vaccine
doxycycline enhances the effects of cisatracurium
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
ferric meltol inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
ferrous fumarate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
ferrous gluconate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
ferrous sulfate inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
iron dextran inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
iron sucrose inhibits the GI absorption of doxycycline (provide 2 hours difference between both drugs)
exhibit the risk of pseudotumor cerebri
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may inhibit the GI absorption of doxycycline (provide 2 hours difference between both drugs)
it may increase risk of nephrotoxicity
it may enhance the photosensitizing effects of the other drug
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
interaction of both drugs may lead to respiratory depression
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects doxy
interaction of both drugs may lead to respiratory depression
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
tetracycline may decrease the therapeutic effects of penicillins by interfering with its bactericidal effects
interaction of both drugs may lead to respiratory depression
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
doxycycline can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
nafcillin will decrease the effect of action of doxycycline by antagonism.
Therapeutic efficacy of azlocillin may decrease.
bismuth subsalicylate reduces the levels of doxycycline by inhibiting gastrointestinal absorption
when both drugs are combined, there may be a decrease in levels of doxycycline
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with doxycycline it decreases the effects of action of drug by antagonism effect
amoxicillin and clavulanate potassium
when amoxicillin combines with doxycycline it decreases the effects of action of drug by antagonism effect
omeprazole amoxicillin and clarithromycin
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
metronidazole/tetracycline/bismuth subsalicylateÂ
the levels of doxycycline can be reduced by bismuth subsalicylate by inhibiting gastrointestinal absorption
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
cholestyramine reduces the therapeutic effects of doxycycline by inhibiting GI absorption
didanosine reduces the therapeutic effects of doxycycline by inhibiting GI absorption
doxycycline may interfere with the intestinal flora and reduce the effects of digoxin
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
estrogens conjugated synthetic
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
it reduces the therapeutic effects of doxycycline by inhibiting GI absorption
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
tetracycline reduces the therapeutic effects of methotrexate by suppressing GI metabolism by intestinal flora
increases the adverse toxic effects
increases the adverse toxic effects
doxycycline enhances the therapeutic effects of warfarin
zinc may reduce the GI absorption and effects of doxycycline
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
tetracyclines may diminish the therapeutic effect of penicillins
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
they increase the effect of neuromuscular blockage of neuromuscular-blocking agents
may reduce the therapeutic effect of penicillins
amoxicillin and clavulanate potassium
may reduce the therapeutic effect of penicillins
may reduce the therapeutic effect of penicillins
may reduce the therapeutic effect of penicillins
may reduce the therapeutic effect of penicillins
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
It may enhance the toxicity when combined with mipomersen
They may diminish the absorption when combined with bile acid sequestrants
It may enhance the effect when combined with cannabidiol by affecting CYP3A4 metabolism
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
sodium picosulfate, citric acid, and magnesium oxide
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
sodium picosulfate, citric acid, and magnesium oxide
may diminish the effect of each other when combined
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
doxycycline leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When doxycycline is used together with calcium levulinate, this leads to a reduced concentration serum of doxycycline
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
doxycycline: it may decrease the serum concentration of gestodene
doxycycline: it may decrease the therapeutic efficacy of with pheneticillin
piperacillin decreases the effectiveness of doxycycline by antagonism.
When bacampicillin combines with doxycycline, the effect and action of bacampicillin decreases.
When penicillin G benzathine combines with doxycycline, the action and effectiveness of penicillin G benzathine decreases.
when both drugs are combined, there may be a decreasing effect of ceftriaxone by pharmacodynamic antagonism  
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
The interaction may depress the therapeutic efficacy of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may increase the hypoglycemic effect of sulfonylureas
may increase the hypoglycemic effect of sulfonylureas
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may diminish the absorption of magnesium salts
may diminish the absorption of magnesium salts
it may diminish the excretion rate when combined with corifollitropin alfa resulting in an enhanced serum level
It may enhance the risk of adverse effects when combined with Tetracyclines
may diminish the absorption when combined with tetracyclines
tetracyclines efficacy may be reduced when calcimax is used in combination
tetracyclines efficacy may be reduced when calcimax is used in combination
tetracyclines efficacy may be reduced when calcimax is used in combination
tetracyclines efficacy may be reduced when calcimax is used in combination
tetracyclines efficacy may be reduced when calcimax is used in combination
doxycycline may enhance the therapeutic effects of antithrombin alfa
doxycycline may enhance the therapeutic effects of antithrombin III
doxycycline may enhance the therapeutic effects of argatoban
doxycycline may decrease the therapeutic effects of the balsalazide
doxycycline may decrease the therapeutic effects of the bemiparin
doxycycline may decrease the therapeutic effects of the biotin
doxycycline may increase the therapeutic effects of the bivalirudin
colestipol reduces the therapeutic effects of doxycycline by affecting GI absorption
doxycycline increases the effects of dalteparin by an unknown mechanism
doxycycline increases the effects of enoxaparin by an unknown mechanism
doxycycline increases the effects of fondaparinux by an unknown mechanism
doxycycline increases the effects of heparin by an unknown mechanism
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
doxycycline may reduce the therapeutic effect of the other drug by affecting intestinal flora
Actions and SpectrumÂ
Doxycycline is a bacteriostatic antibiotic that disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit which effectively targets both Gram+ve and Gram-ve bacteria and malaria causing parasites.Â
Frequency not defined:Â
Esophageal ulcerÂ
Increased liver enzymesÂ
Visual disturbanceÂ
DysphagiaÂ
GlossitisÂ
NauseaÂ
VomitingÂ
DiarrheaÂ
HepatotoxicityÂ
Reversible and more frequent photosensitivity reactionÂ
Dose-related diabetes insipidus Â
Discoloration of teethÂ
Superinfection, monilialÂ
None
Contraindication/Caution:Â
None
Pregnancy considerations: Â Â
pregnancy category D. Â
Lactation: Â
Excretion of drug into human milk is knownÂ
Pregnancy category:Â
Pharmacology:Â
Pharmacodynamics:Â
Doxycycline works in various tissues by crossing multiple membranes and reaches the target site. Its bacteriostatic action during protein synthesisÂ
is to inhibit the bacterial growth by binding to the 30S prokaryotic ribosomal unit. This prevents the association of aminoacyl-tRNA with the ribosomal A site stalling the elongation phase and preventing essential protein production ultimately kills the bacterial growth.Â
Pharmacokinetics:Â
AbsorptionÂ
It has rapid absorptionÂ
Elimination:Â
Excreted through urine and fecesÂ
Administration:Â
It is given orally, and dose is adjusted based on severity of the infection and treatment response.Â
Patient information leafletÂ
Generic Name: doxycyclineÂ
Why do we use doxycycline?Â
Doxycycline is indicated for the treatment of infections occurred by gram-positive and gram-negative bacteria.Â
It is also used in treatment of rickettsial infections and sexually transmitted infections.Â
It is effective in management of acute intestinal amebiasis and acne vulgaris.Â
It is indicated for treatment of inflammatory lesions of rosacea in adults.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
